Novartis AG (NVS)
After hours:
| Previous close | 97.34 |
| Open | 97.75 |
| Bid | 96.47 x 800 |
| Ask | 97.39 x 800 |
| Day's range | 97.07 - 97.91 |
| 52-week range | 92.19 - 108.78 |
| Volume | |
| Avg. volume | 1,607,796 |
| Market cap | 198.471B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.11 |
| EPS (TTM) | 4.40 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.78 (3.88%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | 114.51 |
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
- Reuters
UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. "The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.
ReutersNovartis to buy radiology drug specialist Mariana for $1 billion
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. "The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities," Novartis said in a statement.
